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Immunologic Corneal Graft Rejection after 
Administration of Topical Latanoprost:  
a Report of Two Patients
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1Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, California, USA
2Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Purpose: To report endothelial corneal graft rejection after administration of topical 
latanoprost eye drops.
Case Report: Two eyes of two patients with a history of multiple intraocular 
procedures prior to penetrating keratoplasty developed endothelial graft rejection one 
month after administration of topical latanoprost. Cystoid macular edema developed 
simultaneously in one patient.
Conclusion: Latanoprost may trigger endothelial graft rejection in susceptible eyes.
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INTRODuCTION
Latanoprost (Xalatan, Pharmacia and Upjohn, 
Kalamazoo, MI, USA) has been associated 
with a number of ocular side effects including 
increased iris pigmentation, elongation of cilia, 
hypertrichosis, and skin pigmentation.1,2 In 
addition, topical latanoprost has been reported 
to cause uveitis, cystoid macular edema (CME), 
and recurrence of herpes simplex keratitis.3-7 
Cystoid macular edema has mostly occurred 
after complicated cataract surgery. Herein, we 
report the occurrence of endothelial corneal 
graft rejection shortly after starting topical 
latanoprost in 2 eyes with prior penetrating 
keratoplasty (PKP). 
CASE REPORTS
Patient 1
A 68-year-old woman underwent PKP a few 
months after complicated cataract surgery in 
the right eye in 1995. She had a second PKP 
in the same eye in June 2000. After intraocular 
pressure (IOP) became uncontrolled, latanoprost 
was added to her prescription of timolol. Two 
weeks later, best-corrected visual acuity (BCVA) 
was 20/400, slit-lamp examination revealed a 
clear, avascular graft and a quiet eye, IOP was 
57 mmHg. A polymethyl methacrylate (PMMA) 
intraocular lens was observed, centered over an 
open posterior capsule. Vitreous incarceration in 
the cataract incision was present superonasally 
along with extensive iridocorneal adhesions. 
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The optic disc seemed mildly saucerized. 
Moderate pigmentary changes were evident in 
the macula. After adding acetazolamide, IOP 
was reduced to 16 mmHg. Topical dorzolamide 
was substituted for acetazolamide with 
maintenance of IOP control. Two weeks later, 
the patient returned with a decrease in BCVA 
to counting fingers at 1 m having mistakenly 
used latanoprost four times daily. Tonometry 
revealed IOP of 10 mmHg. Sectoral corneal 
edema, multiple white keratic precipitates, 
and mild anterior chamber reaction were 
observed (Figure 1). Cystoid macular edema 
was suspected after fundus examination. 
Latanoprost was immediately discontinued and 
graft rejection was treated with corticosteroids. 
Fluorescein angiography was performed the 
next day and confirmed the presence of CME. 
The rejection episode gradually improved over 
the next few weeks together with resolution of 
corneal edema, inflammatory signs and CME 
while BCVA improved to 20/400.
Patient 2
A 45-year-old man with a history of bilateral 
trabeculectomy for  primary open-angle 
glaucoma, underwent repeat trabeculectomy 
in his right eye with mitomycin C by one of 
the authors (MAJ). One year later, a third 
trabeculectomy with adjunctive mitomycin 
C was performed on the same eye because of 
uncontrolled IOP. Postoperatively, the cornea 
decompensated gradually and a PKP was 
performed. IOP increased gradually after PKP 
and timolol and dorzolamide were started. At 
that point, the graft was clear and avascular. 
Three months after PKP, latanoprost was started 
because of uncontrolled IOP. One month later, 
epithelial and endothelial rejection occurred in 
the same eye. The rejection episode partially 
responded to topical steroids and cyclosporine. 
Moderate residual corneal edema and visual 
acuity of counting fingers prompted a second 
graft in this eye 11 months after the rejection 
episode. Five months after the second PKP, 
the graft remained clear and IOP was under 
control on timolol and dorzolamide.
DISCuSSION
We observed the occurrence of  corneal 
graft rejection shortly after initiating topical 
latanoprost in 2 eyes with previous PKP. To 
our knowledge, this has not been previously 
reported in the literature.
Immunologic graft rejection is particularly 
common during the first year after PKP8 and 
both patients could be considered at high risk 
for graft rejection. Patient 1 had extensive 
peripheral anterior synechiae and vitreous 
incarceration into the cataract incision, while the 
second patient had multiple prior procedures. 
However, both patients had avascular corneas 
before PKP. In addition, more than one year 
had elapsed after PKP in patient 1 when graft 
rejection suddenly occurred. The temporal 
sequence of graft rejection immediately after 
starting latanoprost, is strongly suggestive of 
a possible relationship. 
Since the early days of development of 
prostaglandins for treatment of glaucoma, the 
pro-inflammatory effects of such compounds 
have been a concern. However, a number of 
early pilot studies9-11 suggested that latanoprost 
has little, if any, pro-inflammatory effect. The 
highly selective affinity of latanoprost for 
FP receptors, the subtype of receptors most 
sensitive to prostaglandin F, makes vascular 
effects for latanoprost unlikely, even at high 
concentrations.12 With widespread use of 
Figure 1. Immunologic graft rejection one month after 
starting latanoprost in case 1. The larger arrow shows 
the border between the clear and edematous areas 
of the graft. The small arrow points to inferior keratic 
precipitates.
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latanoprost, it was shown to be rarely associated 
with side effects such as CME and attacks of iritis 
or anterior uveitis.3-6 However, latanoprost has 
been shown to lead to disruption of the blood 
aqueous-barrier and an increased incidence of 
angiographic CME in the early postoperative 
period.13 In a clinical trial comparing latanoprost, 
travoprost, and bimatoprost to placebo in 
aphakic and pseudophakic eyes, eyes receiving 
one of the prostaglandins had higher flare 
values and a higher incidence of CME.14 Both 
complications usually occur in eyes with risk 
factors such as previous complicated surgery 
with a disrupted or absent posterior capsule, 
anterior chamber IOL, or history of anterior 
uveitis. The common denominator for all of the 
above risk factors is persistent disruption of 
the blood-aqueous barrier. However, Schumer 
and colleagues15 have raised doubts whether 
the reports in the literature actually represent 
side effects of latanoprost. Our first patient 
had undergone complicated cataract surgery 
with disruption of the posterior capsule and 
vitreous incarceration into the wound, along 
with two PKPs while the second patient 
had multiple trabeculectomies prior to PKP. 
We hypothesize that multiple, complicated 
interventions probably led to chronic breakdown 
of the blood-aqueous barrier in these patients. 
Although a direct cause-and-effect relationship 
cannot be proven with only two patients, 
the short time interval from initiation of 
latanoprost to graft rejection (about a month in 
both patients) may suggest an association. The 
first patient had erroneously used a four-fold 
higher than usual dose of latanoprost for at 
least two weeks, which might have potentiated 
any pro-inflammatory effect of latanoprost. 
Interestingly, this patient developed CME at 
about the same time as graft rejection, adding 
further support to an association between 
latanoprost and immunologic graft rejection. It 
may be speculated that topical administration 
of latanoprost and breakdown of the blood-
aqueous barrier could have acted synergistically 
and led to graft rejection in these eyes. 
We suggest  that  topical  latanoprost 
may trigger immunologic graft rejection in 
susceptible eyes. Until further studies are 
performed, it seems prudent to use topical 
latanoprost with caution in glaucomatous eyes 
after PKP, especially in the presence of chronic 
breakdown of the blood-aqueous barrier and in 
eyes with other risk factors for graft rejection.
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